M/s. THE Director General. Pharmaceutical Import Profile — Tanzania (DGFT 2022–2026)

Name: M/s. THE Director General. Pharmaceutical Import Records from India — 2 Products, $200.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. THE Director General. — Pharmaceutical Importer Profile (2026) | 2 Products, $200.0K Trade | TransData Nexus

M/s. THE Director General.

Pharmaceutical Importer · Tanzania · Antimalarial & Antiparasitic Focus · $200.0K Total Trade · DGFT Verified

M/s. THE Director General. is a pharmaceutical importer based in Tanzania with a total trade value of $200.0K across 2 products in 1 therapeutic categories. Based on 4 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. THE Director General. sources from 1 verified Indian supplier, with Medopharm accounting for 100.0% of imports.

M/s. THE Director General. — Import Portfolio & Supplier Network

M/s. THE Director General. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. THE Director General.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medopharm	$100.0K	2	100.0%

M/s. THE Director General. sources from 1 verified Indian supplier across 1 distinct formulations. The sourcing is highly concentrated — Medopharm accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does M/s. THE Director General. Import?

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pyrimethamine	Antimalarial & Antiparasitic	$100.0K	2	0.2%	6
2	Sulfadoxine	Antimalarial & Antiparasitic	$100.0K	2	0.2%	6

M/s. THE Director General. imports 2 pharmaceutical products across 1 categories into Tanzania totaling $200.0K.

M/s. THE Director General. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. THE Director General. is a pharmaceutical importer and buyer based in Tanzania, specializing in the procurement of finished pharmaceutical formulations. The company operates as a wholesaler, sourcing medications from international suppliers to distribute within the Tanzanian market. While specific details about its headquarters and parent company are not publicly available, M/s. THE Director General. plays a significant role in the Tanzanian pharmaceutical distribution network, ensuring the availability of essential medications to meet the country's healthcare needs.

2Distribution Network

Information regarding M/s. THE Director General.'s warehouse locations and logistics capabilities is not publicly disclosed. However, as a pharmaceutical importer, the company likely collaborates with established distribution channels within Tanzania to facilitate the storage and delivery of imported medications. The extent of its geographic coverage within Tanzania and potential operations beyond the country's borders remains unspecified.

3Industry Role

M/s. THE Director General. functions primarily as a pharmaceutical wholesaler in Tanzania's supply chain. By importing finished pharmaceutical formulations, the company bridges the gap between international manufacturers and local healthcare providers, ensuring the availability of essential medications across the country. Its role is crucial in maintaining a steady supply of pharmaceuticals to meet the demands of hospitals, clinics, and pharmacies.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. THE Director General.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's sourcing strategy exhibits a high degree of concentration, importing only two products—Pyrimethamine and Sulfadoxine—each valued at $100,000, accounting for 0.2% of the total import share. This singular focus on antimalarial and antiparasitic medications suggests a strategic choice to specialize in a niche therapeutic area, likely driven by the prevalent need for such treatments in Tanzania. The consistent importation of these products over four shipments indicates a stable and ongoing relationship with its sole supplier, MEDOPHARM, which has provided all shipments to date.

2Supply Chain Resilience

M/s. THE Director General.'s supply chain appears to be highly dependent on a single supplier, MEDOPHARM, for its antimalarial and antiparasitic products. This single-source dependency could pose risks related to supply disruptions, price fluctuations, or changes in supplier terms. The lack of diversification in product formulations further underscores this vulnerability. To enhance resilience, the company might consider establishing relationships with additional suppliers and diversifying its product portfolio to mitigate potential risks.

3Strategic Implications

Importing Pharmaceuticals into Tanzania — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Tanzania

1Regulatory Authority & Framework

The Tanzania Medicines and Medical Devices Authority (TMDA) is the primary regulatory body overseeing the importation and exportation of pharmaceutical products in Tanzania. Established under the Tanzania Medicines and Medical Devices Act, Cap. 219, TMDA is responsible for ensuring the safety, efficacy, and quality of medicines and medical devices within the country. Key legislation governing pharmaceutical imports includes the Pharmaceutical and Poisons Act, which outlines the control of manufacture, sales, import, and export of pharmaceutical products. The registration of pharmaceutical products is mandated under these regulations, requiring all imported medicines to be registered with TMDA before they can be marketed in Tanzania.

2Import Licensing & GMP

Importers must obtain an import permit from TMDA to legally import pharmaceutical products into Tanzania. The application process involves submitting necessary documentation, including a proforma invoice and evidence of Good Manufacturing Practice (GMP) certification from the supplier. TMDA recognizes GMP certifications from reputable standards such as EU GMP, WHO GMP, and PIC/S. Additionally, importers are required to register their premises with TMDA, ensuring compliance with local regulations and facilitating the importation process.

M/s. THE Director General. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

M/s. THE Director General.'s focus on antimalarial and antiparasitic medications aligns with the high prevalence of malaria and other parasitic diseases in Tanzania. The decision to import Pyrimethamine and Sulfadoxine suggests a strategic approach to address the country's significant healthcare needs in this therapeutic area. Market demand for these treatments is driven by the ongoing efforts to control and eliminate malaria, making them essential components of Tanzania's public health strategy.

2Sourcing Profile

The company's sourcing strategy is centered on importing generic formulations of antimalarial and antiparasitic drugs from India. This approach leverages India's established pharmaceutical manufacturing capabilities and competitive pricing. By focusing on a single supplier, MEDOPHARM, M/s. THE Director General. ensures consistency in product quality and supply. However, this strategy also exposes the company to risks associated with single-source dependency.

3Market Positioning

Based on its product mix, M/s. THE Director General. serves the Tanzanian market segment that requires antimalarial and antiparasitic treatments. This includes hospitals, clinics, and pharmacies that provide care to patients affected by these diseases. The company's role is pivotal in ensuring the availability of these essential medications, thereby supporting the broader healthcare infrastructure in Tanzania.

Seller's Guide — How to Become a Supplier to M/s. THE Director General.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Tanzanian market by offering alternative sources for antimalarial and antiparasitic medications. By providing competitive pricing, reliable delivery schedules, and adherence to TMDA's quality standards, new suppliers can meet the existing demand and potentially expand the product offerings of M/s. THE Director General. Diversifying the supplier base could also enhance supply chain resilience and reduce dependency on a single source.

2Requirements & Qualifications

Indian exporters seeking to supply M/s. THE Director General. and the Tanzanian market must ensure that their products are registered with TMDA and manufactured in facilities that hold recognized GMP certifications. Compliance with TMDA's labeling requirements, including the use of English or Swahili language, is mandatory. Additionally, exporters should be prepared to provide all necessary documentation, such as proforma invoices and certificates of analysis, to facilitate the importation process.

3How to Approach

Frequently Asked Questions — M/s. THE Director General.

What products does M/s. THE Director General. import from India?

M/s. THE Director General. imports 2 pharmaceutical products across 1 categories. Top imports: Pyrimethamine ($100.0K), Sulfadoxine ($100.0K).

Who supplies pharmaceuticals to M/s. THE Director General. from India?

M/s. THE Director General. sources from 1 verified Indian suppliers. The primary supplier is Medopharm (100.0% of imports, $100.0K).

What is M/s. THE Director General.'s total pharmaceutical import value?

M/s. THE Director General.'s total pharmaceutical import value from India is $200.0K, based on 4 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. THE Director General. focus on?

M/s. THE Director General. imports across 1 categories. The largest: Antimalarial & Antiparasitic (100.0%).

Get Full M/s. THE Director General. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.